Spi14 Inhibitors
Spiroindolines, commonly referred to as Spi14 inhibitors, constitute a chemical class characterized by a distinctive spiro-connection between an indoline system and another cyclic component. This structural motif is of particular interest in the field of chemistry due to its unique three-dimensional conformation. The Spi14 nomenclature typically denotes a specific target or activity associated with this molecular framework, although without context related to their function or application, the details remain focused solely on their chemistry. The spiroindolines are known for their rigidity and the spiro junction often imparts a pronounced degree of stereochemical complexity to these molecules, which can significantly influence their physical and chemical properties.
The synthesis of Spi14 inhibitors involves advanced organic synthesis techniques that enable the precise construction of the spiro framework. These methods often employ strategies such as intramolecular cyclization reactions, which can be facilitated by various catalysts to form the spiro bond efficiently. The indoline moiety, a bicyclic structure composed of a benzene ring fused to a nitrogen-containing pyrrolidine ring, serves as a key component of these compounds. The fusion to an additional cyclic structure through a spiro connection results in a molecule that is chiral at the spiro center. The stereochemistry at this center can affect the compound's conformation and, consequently, its chemical reactivity. The precise control over the stereochemistry of the spiro center is of significant importance during the synthesis of Spi14 inhibitors, as it can have profound effects on the compound's overall profile.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it prevents the activation of AKT signaling pathway, which may be necessary for Spi14 activation or stabilization. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), which is a key downstream effector in the PI3K/AKT pathway, potentially reducing the activity of Spi14 if it is regulated by mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K, which could lead to the downregulation of AKT-mediated pathways and potentially inhibit Spi14 if it is part of the PI3K/AKT signaling cascade. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK1/2, which are upstream activators of ERK1/2 in the MAPK pathway. Inhibition of this pathway could indirectly decrease Spi14 activity if Spi14 is downstream of MAPK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a non-competitive inhibitor of MEK1/2, also in the MAPK pathway. By inhibiting MEK, it could indirectly inhibit Spi14 if Spi14 functions are modulated by MAPK-dependent signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The inhibition of p38 MAPK can lead to the downregulation of pathways that could indirectly modulate Spi14 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which may play a role in stress response pathways. Inhibition of JNK signaling could reduce Spi14 activity if Spi14 is responsive to cellular stress signals mediated by JNK. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM447439 is an Aurora kinase inhibitor. If Spi14 is involved in the cell cycle regulation where Aurora kinases play a crucial role, its inhibition could result in decreased Spi14 function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasome, it may prevent the degradation of regulatory proteins that inhibit Spi14, leading to a decrease in Spi14 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor, leading to an increase in cytosolic calcium levels and potentially perturbing calcium-dependent signaling pathways that could regulate Spi14 activity. | ||||||